GRI Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GRI Bio, Inc. on September 8, 2026. The Company is a Delaware corporation with its principal executive offices in La Jolla, California. The report discloses updates regarding corporate presentations and clinical trial data for its lead candidate, GRI-0621.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial operational updates and does not contain audited financial statements or quarterly results.
Material Changes and Operational Updates
- Corporate Presentation: On September 8, 2026, the Company posted an updated corporate presentation to its investor relations website (Exhibit 99.1).
- Clinical Data Announcement: The Company issued a press release (Exhibit 99.2) announcing new translational biomarker data from the Phase 2a study evaluating GRI-0621 (oral tazarotene) in patients with idiopathic pulmonary fibrosis.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future earnings, or a detailed risk factor analysis. The primary focus is the dissemination of clinical data and corporate materials. The Company notes that the information in Item 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Review Exhibit 99.2 for the specific details of the translational biomarker data from the Phase 2a study of GRI-0621.
- Access the updated corporate presentation (Exhibit 99.1) on the Company's website for the latest strategic overview.
- Verify the Company's current cash position and burn rate in the most recent 10-Q or 10-K filing, as this 8-K does not contain financial data.
- Confirm the regulatory status and next steps for the idiopathic pulmonary fibrosis program following the data release.